These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα. Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154 [TBL] [Abstract][Full Text] [Related]
24. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα. Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339 [TBL] [Abstract][Full Text] [Related]
25. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor. Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802 [TBL] [Abstract][Full Text] [Related]
27. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574 [TBL] [Abstract][Full Text] [Related]
28. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Chowdhury AR; Sharma S; Mandal S; Goswami A; Mukhopadhyay S; Majumder HK Biochem J; 2002 Sep; 366(Pt 2):653-61. PubMed ID: 12027807 [TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388 [TBL] [Abstract][Full Text] [Related]
30. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Peebles KA; Baker RK; Kurz EU; Schneider BJ; Kroll DJ Biochem Pharmacol; 2001 Oct; 62(8):1059-70. PubMed ID: 11597574 [TBL] [Abstract][Full Text] [Related]
31. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519 [TBL] [Abstract][Full Text] [Related]
33. Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα. Pogorelčnik B; Brvar M; Žegura B; Filipič M; Solmajer T; Perdih A ChemMedChem; 2015 Feb; 10(2):345-59. PubMed ID: 25522133 [TBL] [Abstract][Full Text] [Related]
34. Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors. Park S; Kadayat TM; Jun KY; Thapa Magar TB; Bist G; Shrestha A; Lee ES; Kwon Y Eur J Med Chem; 2017 Jan; 125():14-28. PubMed ID: 27643560 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors. Wambang N; Schifano-Faux N; Aillerie A; Baldeyrou B; Jacquet C; Bal-Mahieu C; Bousquet T; Pellegrini S; Ndifon PT; Meignan S; Goossens JF; Lansiaux A; Pélinski L Bioorg Med Chem; 2016 Feb; 24(4):651-60. PubMed ID: 26740155 [TBL] [Abstract][Full Text] [Related]
37. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase. Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529 [TBL] [Abstract][Full Text] [Related]
38. HU-331 is a catalytic inhibitor of topoisomerase IIα. Regal KM; Mercer SL; Deweese JE Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338 [TBL] [Abstract][Full Text] [Related]
39. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors. Bergant K; Janezic M; Perdih A Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein. Jain HD; Zhang C; Zhou S; Zhou H; Ma J; Liu X; Liao X; Deveau AM; Dieckhaus CM; Johnson MA; Smith KS; Macdonald TL; Kakeya H; Osada H; Cook JM Bioorg Med Chem; 2008 Apr; 16(8):4626-51. PubMed ID: 18321710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]